Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 -0.48%62 EV-to-EBIT is 8.72 as of Sep. 03, 2026, which is 7% below its 10-year median of 9.38. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円694.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 107 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 85.05% on this metric.
The historical rank and industry rank for Human Metabolome Technologies's EV-to-EBIT or its related term are showing as below:
TSE:6090'
s EV-to-EBIT Range Over the Past 10 Years
Min: -286.28 Med: 9.38 Max: 190.24
Current: 8.73
During the past 13 years, the highest EV-to-EBIT of Human Metabolome Technologies was 190.24. The lowest was -286.28. And the median was 9.38.
TSE:6090's EV-to-EBIT is ranked better than 85.05% of 107
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.9
vs TSE:6090: 8.73
Human Metabolome Technologies (TSE:6090) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Human Metabolome Technologies's Enterprise Value for the quarter that ended in Mar. 2026 was 円2,449 Mil.
Human Metabolome Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円227 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies EV-to-EBIT Related Terms
Human Metabolome Technologies EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Human Metabolome Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's EV-to-EBIT falls into.
Human Metabolome Technologies's current Enterprise Value is 円1,978 Mil.
Human Metabolome Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円227 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a EV-to-EBIT of 8.72 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Human Metabolome Technologies and its competitors. This is near median its historical median of 9.38. According to the industry distribution chart, Human Metabolome Technologies ranks #16 out of 107 companies in the Medical Diagnostics & Research industry, placing it in the top 15%.
Is Human Metabolome Technologies' EV-to-EBIT too high?
Human Metabolome Technologies' current EV-to-EBIT of 8.72 is near median its 10-year median of 9.38. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.90. Human Metabolome Technologies' value of 8.72 is 63.5% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #16 out of 107 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #16 out of 107 companies for EV-to-EBIT. This places Human Metabolome Technologies in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 23.90. Human Metabolome Technologies' value of 8.72 is 63.5% below this benchmark. While the company's 10-year median is 9.38 vs. the industry median of 23.90, Human Metabolome Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.90, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current EV-to-EBIT of 8.72 is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current EV-to-EBIT is 8.72, which is near median its own 10-year median of 9.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円694.59, compared to a current price of 円617.00 — trading 11.2% below its estimated fair value. The current EV-to-EBIT is 8.72, which is near median its 10-year median of 9.38 and 63.5% below the Medical Diagnostics & Research industry median of 23.90. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current EV-to-EBIT is 8.72 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円617.00 is trading 11.2% below its estimated GF Value™ of 円694.59.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
EV-to-EBIT: 8.72 (near median its 10-year median of 9.38)
GF Value™: 円694.59 vs. price of 円617.00 (11.2% below fair value)
Industry Position: 63.5% below the Medical Diagnostics & Research median (#16 of 107)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
